{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:38:42Z","timestamp":1786995522988,"version":"build-2736575974"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":150,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.pcad.2024.07.002","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T01:00:09Z","timestamp":1721869209000},"page":"38-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Anthracyclines, Diastolic Dysfunction and the road to Heart Failure in Cancer survivors: An untold story"],"prefix":"10.1016","volume":"86","author":[{"given":"Massimiliano","family":"Camilli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Ferdinandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Salvatorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierantonio","family":"Menna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Minotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2024.07.002_bb0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pcad.2024.07.002_bb0010","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/ejhf.1985","article-title":"The cancer patient and cardiology","volume":"22","author":"Zamorano","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2024.07.002_bb0015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.pcad.2024.07.002_bb0020","first-page":"818","article-title":"Diastolic function in heart failure with reduced ejection fraction: the overlooked prognosticator?","volume":"7","author":"Daubert","year":"2019","journal-title":"J Am Coll Cardiol: Heart Fail"},{"key":"10.1016\/j.pcad.2024.07.002_bb0025","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.amjcard.2009.01.024","article-title":"Usefulness of a combination of systolic function by left ventricular ejection fraction and diastolic function by E\/E\u2032 to predict prognosis in patients with heart failure","volume":"103","author":"Hirata","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0030","first-page":"808","article-title":"Diastolic determinants of excess mortality in heart failure with reduced ejection fraction","volume":"7","author":"Benfari","year":"2017","journal-title":"J Am Coll Cardiol: Heart Fail"},{"key":"10.1016\/j.pcad.2024.07.002_bb0035","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/clc.22710","article-title":"Prognostic impact of diastolic dysfunction in systolic heart failure-a cross-project analysis from the German competence network heart failure","volume":"40","author":"L\u00fcers","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0040","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0735-1097(87)80099-2","article-title":"Alterations in left ventricular diastolic function with doxorubicin therapy","volume":"9","author":"Lee","year":"1987","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MNM.0000000000000941","article-title":"Diastolic dysfunction can precede systolic dysfunction on MUGA in cancer patients receiving trastuzumab-based therapy","volume":"40","author":"Klein","year":"2019","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.pcad.2024.07.002_bb0050","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.amjcard.2018.12.046","article-title":"Serial measurements of left ventricular systolic and diastolic function by cardiac magnetic resonance imaging in patients with early stage breast cancer on trastuzumab","volume":"123","author":"Song","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0055","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/0002-8703(89)90077-X","article-title":"Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics","volume":"118","author":"Marchandise","year":"1989","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2024.07.002_bb0060","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0735-1097(92)90138-D","article-title":"Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans","volume":"20","author":"Stoddard","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.euje.2005.04.009","article-title":"Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study","volume":"7","author":"Tassan-Mangina","year":"2006","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.pcad.2024.07.002_bb0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12253-008-9013-4","article-title":"Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study","volume":"14","author":"Nagy","year":"2008","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.pcad.2024.07.002_bb0075","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","article-title":"Early detection and prediction of cardiotoxicity in chemotherapy-treated patients","volume":"107","author":"Sawaya","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0080","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.echo.2010.12.004","article-title":"Tissue-Doppler assessment of cardiac left ventricular function during short-term adjuvant epirubicin therapy for breast cancer","volume":"24","author":"Appel","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.pcad.2024.07.002_bb0085","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/ehjci\/jes139","article-title":"Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy","volume":"14","author":"Stoodley","year":"2013","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2024.07.002_bb0090","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.echo.2013.10.008","article-title":"Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer","volume":"27","author":"Florescu","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.pcad.2024.07.002_bb0095","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5603\/CJ.a2013.0150","article-title":"Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up","volume":"21","author":"Elitok","year":"2014","journal-title":"Cardiol J"},{"key":"10.1016\/j.pcad.2024.07.002_bb0100","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.2014-0500","article-title":"Diastolic dysfunction following anthracycline-based chemotherapy in breast cancer patients: incidence and predictors","volume":"20","author":"Serrano","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.pcad.2024.07.002_bb0105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2024.07.002_bb0110","doi-asserted-by":"crossref","first-page":"70072","DOI":"10.18632\/oncotarget.19585","article-title":"Longitudinal rotation: a new way to detect the cardiotoxicity of anthracycline-based chemotherapy in breast cancer patients","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pcad.2024.07.002_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175544","article-title":"Anthracyclines induce early changes in left ventricular systolic and diastolic function: a single Centre study","volume":"12","author":"Boyd","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.pcad.2024.07.002_bb0120","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/ehjci\/jex033","article-title":"2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility","volume":"18","author":"Santoro","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2024.07.002_bb0125","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.2147\/CMAR.S166481","article-title":"Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer","volume":"10","author":"Cochera","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.pcad.2024.07.002_bb0130","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000486761","article-title":"Early diastolic dysfunction after cancer chemotherapy: primary endpoint results of a multicenter cardio-oncology study","volume":"63","author":"Calabrese","year":"2018","journal-title":"Chemotherapy"},{"key":"10.1016\/j.pcad.2024.07.002_bb0135","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jcmg.2019.07.018","article-title":"Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy","volume":"13","author":"Upshaw","year":"2020","journal-title":"J Am Coll Cardiol Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2024.07.002_bb0140","first-page":"53","article-title":"Lifestyle and cardiovascular risk factors associated with heart failure subtypes in postmenopausal breast cancer survivors","volume":"4","author":"Reding","year":"2022","journal-title":"J Am Coll Cardiol: CardioOncol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0145","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10549-022-06586-4","article-title":"Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer","volume":"193","author":"Kwan","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.pcad.2024.07.002_bb0150","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.22.00111","article-title":"Toward a better understanding of the differential impact of heart failure phenotypes after breast Cancer","volume":"40","author":"Reding","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0155","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/ehjci\/jeab154","article-title":"Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging","volume":"23","author":"Smiseth","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2024.07.002_bb0160","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.pcad.2020.04.011","article-title":"Heart failure with preserved ejection fraction diagnosis and treatment: an updated review of the evidence","volume":"63","author":"Del Buono","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2024.07.002_bb0165","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/cells9010242","article-title":"Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding","volume":"9","author":"Simmonds","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.pcad.2024.07.002_bb0170","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction","volume":"131","author":"Mohammed","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2024.07.002_bb0175","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004311","article-title":"Relaxation and the role of calcium in isolated contracting myocardium from patients with hypertensive heart disease and heart failure with preserved ejection fraction","volume":"10","author":"Runte","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2024.07.002_bb0180","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.pcad.2024.07.002_bb0185","doi-asserted-by":"crossref","first-page":"11293","DOI":"10.1021\/bi971475e","article-title":"Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin","volume":"36","author":"V\u00e1squez-Vivar","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.pcad.2024.07.002_bb0190","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jacc.2017.05.019","article-title":"Arginine-nitric oxide metabolites and cardiac dysfunction in patients with breast cancer","volume":"70","author":"Finkelman","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0195","first-page":"861","article-title":"Role of endothelium in doxorubicin-induced cardiomyopathy","volume":"3","author":"Luu","year":"2018","journal-title":"J Am Coll Cardiol: Basic Transl Sci"},{"key":"10.1016\/j.pcad.2024.07.002_bb0200","doi-asserted-by":"crossref","first-page":"8290","DOI":"10.1074\/jbc.M308033200","article-title":"Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes","volume":"279","author":"Lim","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pcad.2024.07.002_bb0205","doi-asserted-by":"crossref","first-page":"H1453","DOI":"10.1152\/ajpheart.00554.2015","article-title":"Drug-induced mitochondrial dysfunction and cardiotoxicity","volume":"309","author":"Varga","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0210","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/jpet.113.204057","article-title":"Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs","volume":"346","author":"Minotti","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pcad.2024.07.002_bb0215","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10741-020-10063-9","article-title":"Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets","volume":"26","author":"Fabiani","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.pcad.2024.07.002_bb0220","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2024.07.002_bb0225","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","article-title":"Heart failure with mid-range or mildly reduced ejection fraction","volume":"19","author":"Savarese","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0230","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.pcad.2024.07.002_bb0235","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1124\/jpet.117.242388","article-title":"Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin","volume":"362","author":"Salvatorelli","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pcad.2024.07.002_bb0240","first-page":"139","article-title":"From cardiac anthracycline accumulation to real-life risk for early diastolic dysfunction: a translational approach","volume":"4","author":"Minotti","year":"2022","journal-title":"J Am Coll Cardiol: CardioOncol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0245","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0250","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"ESMO guidelines committee. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0255","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2024.07.002_bb0260","doi-asserted-by":"crossref","unstructured":"Armenian SH, Hudson MM, Mulder RL, et al.; International late effects of childhood Cancer guideline harmonization group. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the international late effects of childhood Cancer guideline harmonization group. Lancet Oncol 2015; 16:e123\u201336. doi: https:\/\/doi.org\/10.1016\/S1470-2045(14)70409-7.","DOI":"10.1016\/S1470-2045(14)70409-7"},{"key":"10.1016\/j.pcad.2024.07.002_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165262","article-title":"Body surface area and baseline blood pressure predict subclinical anthracycline cardiotoxicity in women treated for early breast cancer","volume":"11","author":"Kotwinski","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.pcad.2024.07.002_bb0270","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1200\/JCO.2016.67.4846","article-title":"Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis","volume":"34","author":"Guenancia","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0275","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2024.07.002_bb0280","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the heart failure association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2024.07.002_bb0285","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0290","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jacc.2021.07.042","article-title":"Coronary microvascular dysfunction across the spectrum of cardiovascular diseases: JACC state-of-the-art review","volume":"78","author":"Del Buono","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0295","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.cardfail.2016.01.011","article-title":"Optimizing the management of heart failure with preserved ejection fraction in the elderly by targeting comorbidities (OPTIMIZE-HFPEF)","volume":"22","author":"Fu","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.pcad.2024.07.002_bb0300","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/eurheartj\/ehy365","article-title":"Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications","volume":"40","author":"Ferdinandy","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2024.07.002_bb0305","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1038\/s41467-022-31544-5","article-title":"Sex differences in heart mitochondria regulate diastolic dysfunction","volume":"13","author":"Cao","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.pcad.2024.07.002_bb0310","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025578","article-title":"Genetic determinants of body mass index and fasting glucose are mediators of grade 1 diastolic dysfunction","volume":"11","author":"Vaitinadin","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2024.07.002_bb0315","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11010-012-1546-x","article-title":"Circulating miRNA as novel markers for diastolic dysfunction","volume":"376","author":"Nair","year":"2013","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.pcad.2024.07.002_bb0320","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","article-title":"Genetic variants associated with Cancer therapy-induced cardiomyopathy","volume":"140","author":"Garcia-Pavia","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2024.07.002_bb0325","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children\u2019s Oncology Group","volume":"30","author":"Blanco","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0330","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/eurjhf\/hfq175","article-title":"Familial dilated cardiomyopathy: another risk factor for anthracycline-induced cardiotoxicity?","volume":"12","author":"van den Berg","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2024.07.002_bb0335","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.yjmcc.2022.03.010","article-title":"Genetics of cancer therapy-associated cardiotoxicity","volume":"167","author":"Kim","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0340","first-page":"402","article-title":"Genetic predisposition to cardiovascular disease in patients with Cancer","volume":"5","author":"Farmakis","year":"2023","journal-title":"J Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.pcad.2024.07.002_bb0345","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","article-title":"Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study","volume":"13","author":"Gianni","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0350","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1124\/jpet.106.103846","article-title":"Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies","volume":"318","author":"Salvatorelli","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pcad.2024.07.002_bb0355","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1200\/JCO.1997.15.5.1906","article-title":"Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer","volume":"15","author":"Gianni","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0360","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/mi.5.3.6","article-title":"The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine","volume":"5","author":"Peng","year":"2005","journal-title":"Mol Interv"},{"key":"10.1016\/j.pcad.2024.07.002_bb0365","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.07.002_bb0370","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40959-021-00100-3","article-title":"Damage to cardiac vasculature may be associated with breast cancer treatment induced cardiotoxicity","volume":"7","author":"Hoffman","year":"2021","journal-title":"Cardio-Oncology"},{"key":"10.1016\/j.pcad.2024.07.002_bb0375","first-page":"805","article-title":"Trastuzumab cardiotoxicity after anthracycline exposure constitutes a complex and clinically important entity","volume":"7","author":"Ewer","year":"2019","journal-title":"J Am Coll Cardiol: Heart Fail"},{"key":"10.1016\/j.pcad.2024.07.002_bb0380","first-page":"678","article-title":"Clinical, echocardiographic, and biomarker associations with impaired cardiorespiratory fitness early after HER2-targeted breast cancer therapy","volume":"3","author":"Bonsignore","year":"2021","journal-title":"J Am Coll Cardiol: CardioOncol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0385","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0360-3016(00)01531-5","article-title":"Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results","volume":"49","author":"Hardenbergh","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.pcad.2024.07.002_bb0390","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1634\/theoncologist.2014-0299","article-title":"Diastolic dysfunction occurs early in HER2-positive breast cancer patients treated concurrently with radiation therapy and trastuzumab","volume":"20","author":"Cao","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.pcad.2024.07.002_bb0395","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1161\/CIRCULATIONAHA.116.025434","article-title":"Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer","volume":"135","author":"Saiki","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2024.07.002_bb0400","series-title":"Atlas of Imaging in Cardio-Oncology","first-page":"1","author":"Steingart","year":"2021"},{"key":"10.1016\/j.pcad.2024.07.002_bb0405","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.echo.2008.11.023","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography","volume":"22","author":"Nagueh","year":"2009","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.pcad.2024.07.002_bb0410","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/ehjci\/jex252","article-title":"Impact of the 2016 ASE\/EACVI recommendations on the prevalence of diastolic dysfunction in the general population","volume":"19","author":"Almeida","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2024.07.002_bb0415","first-page":"377","article-title":"Prevalence of diastolic dysfunction in adult survivors of childhood Cancer","volume":"5","author":"Palmer","year":"2023","journal-title":"J Am Coll Cardiol: CardioOncol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0420","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1111\/echo.14782","article-title":"Assessment of left ventricular diastolic function by three-dimensional transthoracic echocardiography","volume":"37","author":"Badano","year":"2020","journal-title":"Echocardiography"},{"key":"10.1016\/j.pcad.2024.07.002_bb0425","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/ehjci\/jeaa415","article-title":"Determinants of left atrial reservoir and pump strain and use of atrial strain for evaluation of left ventricular filling pressure","volume":"23","author":"Inoue","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2024.07.002_bb0430","first-page":"1","article-title":"Left atrial function assessed by speckle tracking echocardiography in anthracycline-induced cardiotoxicity: a case report","volume":"4","author":"Sueta","year":"2020","journal-title":"Eur Heart J Case Rep"},{"key":"10.1016\/j.pcad.2024.07.002_bb0435","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijcard.2021.02.013","article-title":"Left atrial strain changes in patients with breast cancer during anthracycline therapy","volume":"330","author":"Laufer-Perl","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0440","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jacc.2013.03.085","article-title":"Ventricular-arterial coupling, remodeling, and prognosis in chronic heart failure","volume":"62","author":"Ky","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0445","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.jcmg.2015.11.024","article-title":"Noninvasive measures of ventricular-arterial coupling and circumferential strain predict cancer therapeutics-related cardiac dysfunction","volume":"9","author":"Narayan","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2024.07.002_bb0450","doi-asserted-by":"crossref","first-page":"124","DOI":"10.31083\/j.rcm2404124","article-title":"Left ventricular-arterial coupling and vascular function in childhood cancer survivors exposed to anthracycline chemotherapy","volume":"24","author":"Camilli","year":"2023","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.pcad.2024.07.002_bb0455","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jacc.2020.11.044","article-title":"Etiology-dependent impairment of diastolic cardiomyocyte calcium homeostasis in heart failure with preserved ejection fraction","volume":"4","author":"Frisk","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0460","doi-asserted-by":"crossref","first-page":"15851","DOI":"10.1016\/S0021-9258(18)47666-1","article-title":"The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions","volume":"262","author":"Boucek","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pcad.2024.07.002_bb0465","first-page":"1945","article-title":"Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues","volume":"13","author":"Stewart","year":"1993","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pcad.2024.07.002_bb0470","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/128_2007_11","article-title":"Anthracycline cardiotoxicity","volume":"283","author":"Menna","year":"2008","journal-title":"Top Curr Chem"},{"key":"10.1016\/j.pcad.2024.07.002_bb0475","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.114.002882","article-title":"Longitudinal changes in left ventricular diastolic function in a general population","volume":"8","author":"Kuznetsova","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2024.07.002_bb0480","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/CIRCHEARTFAILURE.110.959668","article-title":"The natural history of preclinical diastolic dysfunction: a population-based study","volume":"5","author":"Vogel","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2024.07.002_bb0485","first-page":"237","article-title":"Assessing the risk of progression from asymptomatic left ventricular dysfunction to overt heart failure: a systematic overview and meta-analysis","volume":"4","author":"Echouffo-Tcheugui","year":"2016","journal-title":"J Am Coll Cardiol: Heart Fail"},{"key":"10.1016\/j.pcad.2024.07.002_bb0490","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jcmg.2018.10.039","article-title":"Asymptomatic left ventricular diastolic dysfunction: predicting progression to symptomatic heart failure","volume":"13","author":"Kosmala","year":"2020","journal-title":"J Am Coll Cardiol: Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2024.07.002_bb0495","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jcmg.2019.07.022","article-title":"Breast cancer treatment and diastolic dysfunction: should we worry about relaxing in cardio-oncology?","volume":"13","author":"Thavendiranathan","year":"2020","journal-title":"J Am Coll Cardiol: Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2024.07.002_bb0500","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.jacc.2015.04.013","article-title":"Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude lifetime cohort study","volume":"65","author":"Armstrong","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"suppl","key":"10.1016\/j.pcad.2024.07.002_bb0505","doi-asserted-by":"crossref","first-page":"10021A","DOI":"10.1200\/jco.2014.32.15_suppl.10021","article-title":"Hearts too small for body size after doxorubicin for childhood ALL: Grinch syndrome","volume":"32","author":"Lipshultz","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0510","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1161\/CIRCHEARTFAILURE.115.002883","article-title":"Risk factors for incident hospitalized heart failure with preserved versus reduced ejection fraction in a multiracial cohort of postmenopausal women","volume":"9","author":"Eaton","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2024.07.002_bb0515","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jacc.2005.09.022","article-title":"Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the acute decompensated heart failure National Registry (ADHERE) database","volume":"47","author":"Yancy","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0520","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"OPTIMIZE-HF investigators and hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure. A report from the OPTIMIZE-HF registry","volume":"50","author":"Fonarow","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2019.118532","article-title":"Elastic titin properties and protein quality control in the aging heart","volume":"1867","author":"Salcan","year":"2020","journal-title":"Biochim Biophys Acta-Mol Cell Res"},{"key":"10.1016\/j.pcad.2024.07.002_bb0530","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s10741-019-09820-2","article-title":"Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens","volume":"24","author":"Cadeddu Dessalvi","year":"2019","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.pcad.2024.07.002_bb0535","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"SUCCOUR investigators. Strain-guided management of potentially cardiotoxic cancer therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0540","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jcmg.2022.10.010","article-title":"Cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy: 3-year results of the SUCCOUR trial","volume":"16","author":"Negishi","year":"2023","journal-title":"J Am Coll Cardiol: Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2024.07.002_bb0545","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10741-020-10013-5","article-title":"Effect of beta-blockers on heart failure severity in patients with heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials","volume":"26","author":"Fukuta","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.pcad.2024.07.002_bb0550","doi-asserted-by":"crossref","DOI":"10.1007\/s11897-023-00626-w","article-title":"Multimorbidity in heart failure: leveraging cluster analysis to guide tailored treatment strategies","author":"van de Veerdonk","year":"2023","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.pcad.2024.07.002_bb0555","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/ejhf.1328","article-title":"Empagliflozin directly improves diastolic function in human heart failure","volume":"20","author":"Pabel","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2024.07.002_bb0560","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2024.07.002_bb2000","doi-asserted-by":"crossref","unstructured":"Camilli M, Viscovo M, Maggio L, Bonanni A, Torre I, Pellegrino C, Lamendola P, Tinti L, Teofili L, Hohaus S, Lanza GA, Ferdinandy P, Varga Z, Crea F, Lombardo A, Minotti G. Sodium-glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond. Basic Res Cardiol. 2024 Jun 27. doi: 10.1007\/s00395-024-01059-9. Epub ahead of print. PMID: 38935171.","DOI":"10.1007\/s00395-024-01059-9"},{"key":"10.1016\/j.pcad.2024.07.002_bb0565","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","article-title":"Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis\/stiffness in nondiabetic heart failure: a multimodality study","volume":"14","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol: Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2024.07.002_bb0570","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2024.07.002_bb0575","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1161\/CIRCULATIONAHA.111.048520","article-title":"Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo","volume":"124","author":"Bishu","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2024.07.002_bb0580","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/jpet.119.258178","article-title":"Pharmacology of ranolazine versus common cardiovascular drugs in patients with early diastolic dysfunction induced by anthracyclines or nonanthracycline chemotherapeutics: a phase 2b minitrial","volume":"370","author":"Minotti","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pcad.2024.07.002_bb0585","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/CIRCRESAHA.111.258251","article-title":"Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity","volume":"110","author":"Lovelock","year":"2012","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.pcad.2024.07.002_bb0590","first-page":"149","article-title":"Cardiometabolic comorbidities in cancer survivors: J am Coll Cardiol: CardioOncology state-of-the-art review","volume":"21","author":"Zullig","year":"2022","journal-title":"J Am Coll Cardiol; CardioOncol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0595","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(19)30800-9","article-title":"Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the childhood Cancer survivor study","volume":"21","author":"Suh","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0600","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2016.66.4391","article-title":"Trends in obesity prevalence in adults with a history of cancer: results from the US national health interview survey, 1997 to 2014","volume":"34","author":"Greenlee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120998","article-title":"Acetylation and phosphorylation changes to cardiac proteins in experimental HFpEF due to metabolic risk reveal targets for treatment","volume":"309","author":"Koser","year":"2022","journal-title":"Life Sci"},{"key":"10.1016\/j.pcad.2024.07.002_bb0610","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1249\/MSS.0b013e31823cd16a","article-title":"Exercise training improves diastolic function in heart failure patients","volume":"44","author":"Alves","year":"2012","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.pcad.2024.07.002_bb0615","first-page":"316","article-title":"Acute heart failure 29 years after treatment for childhood cancer","volume":"2","author":"Camilli","year":"2020","journal-title":"J Am Coll Cardiol: CardioOncol"},{"key":"10.1016\/j.pcad.2024.07.002_bb0620","doi-asserted-by":"crossref","unstructured":"Efentakis P, Andreadou I, Iliodromitis KE, et al. Myocardial protection and current cancer therapy: two opposite targets with inevitable cost 2022; Int J Mol Sci 23:14121. doi: https:\/\/doi.org\/10.3390\/ijms232214121.","DOI":"10.3390\/ijms232214121"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062024000999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062024000999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T17:12:06Z","timestamp":1738170726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062024000999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":125,"alternative-id":["S0033062024000999"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2024.07.002","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anthracyclines, Diastolic Dysfunction and the road to Heart Failure in Cancer survivors: An untold story","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2024.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}